| Comment Record|
Mr. Robert Clark ||
2002-02-12 16:22:21 |
Novartis Pharmaceuticals Corp |
Health Professional |
| Comments for FDA General |
1. General Comments
To Whom It May Concern:
Novartis Pharmaceuticals Corporation, East Hanover, NJ in conjunction with Novartis Pharma AG, Basle, Switzerland has reviewed the above cited draft guidance and has the following comments and or observations:
Novartis welcomes the initiative of the FDA to encourage industry to establish ways of easily tracking the remaining number of doses in Multi-dose inhalers. There is certainly a need in this area. However, it is felt that the current draft is perhaps kept too general with little guidance on what the FDA reviewers would actually like to see in submissions of new MDIs.
Furthermore, we suggest that reference is made to dose counter / dose indicator rather than just to dose-counter. To our knowledge, most of the dose counting mechanisms currently under development for MDIs do not foresee a reading by single actuation, but rather count in multiple units of e.g. 10 or 20. The FDA itself seems to be thinking in the direction of dose-indication as an option to dose-counting by allowing color-coding as one way of indicating the remaining doses in an MDI (Section III A.).
In Section III B. it is indicated that The reliability of dose-counters should be established during development under in-vitro-testing ……, as well as clinical use studies…….to obtain information on the technical function….“. We would like the FDA to clarify that they consider this type of
studies as ergonomic studiesand not as clinical studies were they would also like to see clinical efficacy data.
Thank you for the opportunity to comment. If you have any questions, please contact me at (973) 781-7005.
Robert J. Clark
Chemistry, Manufacturing and Controls
Drug Regulatory Affairs
Comments provided in duplicate and sent electronically to http://www.fda.gov/dockets/ecomments